Vepdegestrant: Improved Survival in Advanced Breast Cancer
- An international study reveals that vepdegestrant, an oral proteolysis-targeting chimera ER degrader, significantly extends progression-free survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...
- Mario Campone from the Institut de Cancérologie de l'Ouest Angers-Nantes, involved patients who had previously undergone cyclin-dependent kinase 4 and 6 inhibitor therapy and endocrine therapy.
- Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months for those on vepdegestrant, compared to 2.1 months for those on fulvestrant.
Vepdegestrant, an innovative oral drug, dramatically improves progression-free survival in patients battling advanced breast cancer with ESR1 mutations. This groundbreaking research, unveiled at the ASCO meeting and published in the new England Journal of Medicine, showcases vepdegestrant’s potential to significantly change treatment outcomes for those with the primary_keyword. The phase 3 trial results, led by Dr. Mario Campone, demonstrate a median progression-free survival of 5.0 months for patients on vepdegestrant, compared to 2.1 months with fulvestrant. This advancement, a new targeted therapy, could greatly help individuals facing this challenging illness. The secondary_keyword offers new hope. News Directory 3 is following this closely. What’s the next step on this path to improved care?
Vepdegestrant Boosts Survival in Advanced Breast Cancer with ESR1 Mutations
Updated June 2, 2025
An international study reveals that vepdegestrant, an oral proteolysis-targeting chimera ER degrader, significantly extends progression-free survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients who have ESR1 mutations. The findings, presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, were also published in the New England Journal of Medicine.
The phase 3 trial, led by Dr. Mario Campone from the Institut de Cancérologie de l’Ouest Angers-Nantes, involved patients who had previously undergone cyclin-dependent kinase 4 and 6 inhibitor therapy and endocrine therapy. Participants were randomly assigned to recieve either 200 mg of vepdegestrant daily or 500 mg of fulvestrant.
Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months for those on vepdegestrant, compared to 2.1 months for those on fulvestrant. In the overall patient population, median progression-free survival was similar between the two groups: 3.8 months with vepdegestrant and 3.6 months with fulvestrant. Grade 3 or higher adverse events occurred in 23.4% of the vepdegestrant group and 17.6% of the fulvestrant group. Discontinuation due to adverse events was observed in 2.9% and 0.7% of the respective groups.
The research highlights vepdegestrant as a potential new treatment option for advanced breast cancer, offering improved outcomes for patients with specific genetic mutations. Further studies are needed to assess the long-term efficacy and safety of this novel drug in managing advanced breast cancer and improving overall survival.
“Additional follow-up is needed to further characterize the long-term efficacy and safety of vepdegestrant in this population,” the authors write.
What’s next
Longer-term studies are planned to fully evaluate the benefits of vepdegestrant in treating advanced breast cancer and to monitor any potential long-term side effects. The development of vepdegestrant represents a important advancement in targeted therapies for breast cancer, offering hope for improved patient outcomes.